Expression Of The Serum GST-π Level In Patients With NSCLC And Its Clinical Significance

Objective: To detect the expression of serum glutathione S-transferase-Ï€ (GST-Ï€) level in patients with NSCLC,and to investigate its clinical significance. Methods: GST-Ï€ levels in serm of 46 patients with NSCLC, 19 patients with benign lung diseases and 60 health subjects were detected with ELISA. Forty-six NSCLC patients were given 2 cycles of NVB+DDP chemotherapy and clinical response were evaluated. Results: The mean serm GST-Ï€ level was significantly higher in patients with NSCLC than in those with benign lung disease and health subjects (P<0.05). Twenty-five of 46 patients with NSCLC (54.34%) showed elevated serm GST-Ï€ levels above a cutoff value of 166.14ng/ml (mean+two standard deviations in 60 healthy control subjects). The positive rate was significantly higher in patients with NSCLC than in those with benign lung disease 36.84% and healy subjects 3.33%(P<0.05).The positive rate of surm GST-Ï€ were 57.14% in squamons cell carcinoma and 52.00% in adenocarcinoma (P>0.05) . No correlation was observed between the GST-Ï€ level and age, sex, pathohistology. Of the 46 patients treated with NVB+DDP chemotherapy, 19 patients responded to chemotherapy (overall response rate, 41.30%). For the 25 patients with positive GST-Ï€ expression, 5 patients responded to chemotherapy, response rate was 20%. In the 21 patients with negativeGST-7T expression, 14 patients responded to chemotherapy, respone rate was 66.67%. This difference was statistically significant (P < 0.05). Conclusions: The serm GST-ir level may be a valauble tumor marker for NSCLC, There was no correlation between expression of surm GST-x and age, sex, pathohistology. The response rate of NSCLC patients with GST-ir-negative expression was higher than those with GST-7r-positive. GST-x may be a useful predictor of chemotherapy respone.